Ernexa Therapeutics/$ERNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ernexa Therapeutics
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Ticker
$ERNA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6
ISIN
US1140823089
Website
ERNA Metrics
BasicAdvanced
$19M
-
-$26.98
7.12
-
Price and volume
Market cap
$19M
Beta
7.12
52-week high
$2.75
52-week low
$2.08
Financial strength
Current ratio
0.212
Quick ratio
0.199
Long term debt to equity
-7.042
Total debt to equity
-48.437
Interest coverage (TTM)
-2.38%
Profitability
EBITDA (TTM)
-14.075
Gross margin (TTM)
93.46%
Net profit margin (TTM)
-8,615.70%
Operating margin (TTM)
-2,652.90%
Effective tax rate (TTM)
-0.07%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-32.42%
Return on equity (TTM)
984.70%
Valuation
Price to revenue (TTM)
8.401
Price to book
-1.54
Price to tangible book (TTM)
-1.15
Price to free cash flow (TTM)
-0.312
Free cash flow yield (TTM)
-320.87%
Free cash flow per share (TTM)
-843.89%
Growth
Revenue change (TTM)
365.22%
Earnings per share change (TTM)
-57.73%
3-year earnings per share growth (CAGR)
-65.96%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ernexa Therapeutics stock?
Ernexa Therapeutics (ERNA) has a market cap of $19M as of June 21, 2025.
What is the P/E ratio for Ernexa Therapeutics stock?
The price to earnings (P/E) ratio for Ernexa Therapeutics (ERNA) stock is 0 as of June 21, 2025.
Does Ernexa Therapeutics stock pay dividends?
No, Ernexa Therapeutics (ERNA) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Ernexa Therapeutics dividend payment date?
Ernexa Therapeutics (ERNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ernexa Therapeutics?
Ernexa Therapeutics (ERNA) has a beta rating of 7.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.